{"id":5631,"date":"2023-09-04T03:13:58","date_gmt":"2023-09-04T03:13:58","guid":{"rendered":"https:\/\/cm.vastapps.dev\/tcia-collection\/ispy1\/"},"modified":"2023-09-13T12:00:39","modified_gmt":"2023-09-13T12:00:39","slug":"ispy1","status":"publish","type":"tcia_collection","link":"https:\/\/cm.vastapps.dev\/tcia-collection\/ispy1\/","title":{"rendered":"ISPY1"},"featured_media":0,"template":"","citation-tax":[],"cancer_types":["Breast Cancer"],"citations":[4536,4537,2925],"collection_doi":"10.7937\/K9\/TCIA.2016.HdHpgJLK","collection_download_info":"The ISPY team has provided additional options for download. The significance and download links for these subsets are explained on the Detailed Description<\/u> tab.\n\u00a0Click the Versions tab for more info about data releases.","collection_downloads":[5128,5129,5130],"full_export":"

Summary<\/h1>

ACRIN 6657<\/a> <\/strong> <\/u> was designed as a prospective study to test MRI for ability to predict response to treatment and risk-of-recurrence in patients with stage 2 or 3 breast cancer receiving neoadjuvant chemotherapy (NACT). ACRIN 6657<\/a> <\/strong> <\/u> was conducted as a companion study to CALGB 150007, a correlative science study evaluating tissue-based biomarkers in the setting of neoadjuvant treatment of breast cancer.\u00a0Collectively, CALGB 150007 and ACRIN 6657 formed the basis of the multicenter\u00a0I<\/strong>nvestigation of\u00a0S<\/strong>erial Studies to\u00a0P<\/strong>redict\u00a0Y<\/strong>our\u00a0T<\/strong>herapeutic\u00a0R<\/strong>esponse with\u00a0I<\/strong>maging and moL<\/strong>ecular\u00a0A<\/strong>nalysis (I-SPY TRIAL) breast cancer trial, a study of imaging and tissue-based biomarkers for predicting pathologic complete response (pCR) and recurrence-free survival (RFS). Additional information about the trial is available in the Study Protocol<\/a> and Case Report Forms<\/a>.\u00a0Participant Eligibility and Enrollment<\/span>: Criteria for inclusion were patients enrolling on CALGB 150007 with T3 tumors measuring at least 3 cm in diameter by clinical exam or imaging and receiving neoadjuvant chemotherapy with an\u00a0<\/span>\u00a0anthracycline-cyclophosphamide regimen alone or followed by a taxane. Pregnant patients and those with ferromagnetic prostheses were excluded from the study. The study was open to enrollment from May 2002 to March 2006. 237 patients were enrolled, of which 230 met eligibility criteria.<\/p>

Acknowledgements<\/h3>

This shared data set was provided by David Newitt, PhD and Nola Hylton, PhD from\u00a0the Breast Imaging Research Program at UCSF, in collaboration with\u00a0ACRIN, CALGB, the\u00a0I-SPY TRIAL, and TCIA.\u00a0Many thanks are due to\u00a0 The ACRIN 6657 trial team<\/a> <\/u>,\u00a0 The I-SPY 1 TRIAL team<\/a> <\/u>, and all the patients participating in these studies<\/p>

Funding sources include NIH grants to UCSF (R01 CA132870 and U01 CA151235), ACRIN (UO1 CA079778 and UO1 CA080098), and CALGB (UO1 CA31964 and UO1 CA33601).<\/span> <\/span> <\/span><\/p>

<\/p>